The official pharmaceutical manufacturing page offers custom CDMO services. The group also operates APIs, new-energy electrolyte additives, and synthetic biology products.
2021 · Share issuance to specific investors (historical) · CNY 1 billion raised ↗
LinkedIn company page
Independent company page not verified
Official history states completion in 2021, with year-level precision only. No month/day is invented, and no claim is made that no subsequent refinancing occurred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
1,184,986,596.96
-55,025,545.8 Net income attributable to shareholders of the listed company
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
The current stock short name is Fushine; the reporting legal entity remains Jiangxi Fushine Pharmaceutical Co., Ltd.
Group results in 2026 include contributions from new-energy additives and other businesses and cannot be attributed solely to pharmaceutical CDMO growth.
The FY2025 year-over-year change reflects a narrowing loss from a negative base; Q3 2026 parent-attributable results moved from loss to profit.
2026Q3 (YTD) · Reporting notes
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
The current stock short name is Fushine; the reporting legal entity remains Jiangxi Fushine Pharmaceutical Co., Ltd.
Group results in 2026 include contributions from new-energy additives and other businesses and cannot be attributed solely to pharmaceutical CDMO growth.
The FY2025 year-over-year change reflects a narrowing loss from a negative base; Q3 2026 parent-attributable results moved from loss to profit.
Unaudited. Hong Kong interim reports and A-share nine-month reports cover different periods.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The official pharmaceutical manufacturing page offers custom CDMO services. The group also operates APIs, new-energy electrolyte additives, and synthetic biology products.
The full 2025 annual report and the 2026 first-nine-month report have been obtained.
Program / service
Target / indication
Representative stage
Evidence & scope
Outsourced services/custom R&D (group also sells products)
Services / platform
Evidence of services, not clinical data for a drug candidate
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Complete service-segment revenue, orders, capacity utilization, and project conversion rates have not been separately verified. Group totals are not a substitute for segment figures.
